Popular Articles

Unique Cardiovascular Treatment Readied For Global Market: Proprietary Paccocath(R) Technology Is The Only Drug Eluting Balloon With Clinical Data
MEDRAD Interventional(TM)/Possis(R) announced that it has reached key milestones in bringing the Paccocath(R) Technology closer to market as an option for the over 14 million patients in the United States and Europe who suffer from Peripheral Arterial Disease (PAD). These milestones include the selection of physician investigators for U.S. clinical trials and the completion of a new state-of-the-art manufacturing facility.

We Must Lead The NHS Through "dark And Dangerous Period", Says British Medical Association Consultant Chairman
The health service is entering a "dark and dangerous period" because of the economic crisis, the Chairman of the BMA"s Consultants Committee warned in a speech. Arguing that public money must not be diverted away from patient care into "the pockets of shareholders", Dr Jonathan Fielden called for private management consultants to be "ditched" from the NHS.
News of the day
Deadly Leukemia Stem Cells Found And Eliminated By New Targeted Therapy
New research describes a molecular tool that shows great promise as a therapeutic for human acute myeloid leukemia (AML), a notoriously treatment-resistant blood cancer. The study, published by Cell Press in the July 2nd issue of the journal Cell Stem Cell, describes exciting preclinical studies in which a new therapeutic approach selectively attacks human cancer cells grown in the lab and in animal models of leukemia.
Cardiovascular

Ethics Review Of Research In The Context Of Humanitarian Relief Work

Two articles published this week in the open-access journal PLoS Medicine highlight the need for, and the practicalities of, getting appropriate ethical review of research done in the context of humanitarian relief. An article by Doris Schopper and colleagues describes the functioning of the Mç©decins Sans Frontiç¨res (MSF) independent ethics review board (ERB) and the framework used for ethics review by this board. The board, set up in 2001, currently comprises seven members from around the world, all independent of MSF. In 2008, the last full year of operation, the board reviewed 23 proposals covering a range of topic and study designs. As well as providing an overview the article describes some specific challenging ethical issues encountered by the board since its inception. In concluding the article, the authors say: "International humanitarian organizations such as MSF will be faced with even more complex health problems in the future as the global environment changes. Research to devise and test new interventions will remain an important part of MSF"s agenda, and will most probably increase. As this happens, a major concern will be to ensure that communities in which such research takes place are empowered to become true partners and that vulnerable individuals and groups are effectively protected The ethical oversight provided by the MSF ERB will be crucial in addressing these challenges." The editorial, written by the PLoS Medicine editors, discusses more generally the problems that can arise when research is done in such settings, and notes that ethical oversight of such research needs to be rigorous, but also pragmatic, and suggests what the role of journals should be. As the editorial notes, by supporting initiatives such as the MSF research ethics board, journals can help to address these ethical challenges, at the same time as ensuring that the research they publish adheres to accepted ethical standards. Article By Schopper and Colleagues: Funding: No funding was received for this work. Competing Interests: The authors have declared that no competing interests exist. Citation: "Research Ethics Review in Humanitarian Contexts: The Experience of the Independent Ethics Review Board of Medç©cins Sans Frontiç¨res." Schopper D, Upshur R, Matthys F, Singh JA, Bandewar SS, et al. (2009) PLoS Med 6(7): e1000115. doi:10.1371/journal.pmed.1000115 PLoS Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):